Company profile for BioAge Labs

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

BIOAGE develops drugs to treat aging and its associated diseases. We are backed by Andreessen Horowitz, AME Cloud Ventures, PEAR Ventures, Felicis Ventures, Caffeinated Capital, and others. We have created a unique computational platform that leverages proprietary omics data from large human cohorts to identify the molecular pathways that influence longevity. We then develop drugs that target these pathways and treat specific ...
BIOAGE develops drugs to treat aging and its associated diseases. We are backed by Andreessen Horowitz, AME Cloud Ventures, PEAR Ventures, Felicis Ventures, Caffeinated Capital, and others. We have created a unique computational platform that leverages proprietary omics data from large human cohorts to identify the molecular pathways that influence longevity. We then develop drugs that target these pathways and treat specific age-related diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1445A S 50th St, Richmond, CA 94804, US
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/25/3194764/0/en/BioAge-Labs-to-Present-at-Piper-Sandler-37th-Annual-Healthcare-Conference.html

GLOBENEWSWIRE
25 Nov 2025

https://www.globenewswire.com/news-release/2025/11/07/3183677/0/en/BioAge-Labs-to-Present-at-Jefferies-Global-Healthcare-Conference-in-London.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/11/06/3183250/0/en/BioAge-Labs-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html

GLOBENEWSWIRE
06 Nov 2025

https://www.prnewswire.com/news-releases/hitgen-partner-bioage-labs-initiates-phase-1-clinical-study-of-bge-102-a-novel-brain-penetrant-nlrp3-inhibitor-302554934.html

PR NEWSWIRE
15 Sep 2025

https://www.globenewswire.com/news-release/2025/08/20/3136733/0/en/BioAge-Labs-to-Present-at-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
20 Aug 2025

https://www.globenewswire.com/news-release/2025/08/15/3134242/0/en/BioAge-Labs-Announces-First-Participant-Dosed-in-Phase-1-Clinical-Trial-of-BGE-102-a-Novel-Brain-Penetrant-NLRP3-Inhibitor.html

GLOBENEWSWIRE
15 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty